Skip to content

Clinical Trial for Tanreqing Capsules in the Treatment of Novel Coronavirus Pneumonia (COVID-19)

Clinical Trial for Tanreqing Capsules in the Treatment of Novel Coronavirus Pneumonia (COVID-19)

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000029813
Enrollment
Unknown
Registered
2020-02-14
Start date
2020-02-14
Completion date
Unknown
Last updated
2020-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Sponsors

Shanghai Public Health Clinical Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Those who meet the diagnosis of new coronavirus pneumonia and have clinical classification of low and medium; (2) Those who have been diagnosed with TCM as epidemic-closed lungs; (3) Inpatients aged 18 to 75 years, regardless of gender; (4) Voluntarily receive treatment with the drug and sign informed consent. The informed consent process complies with relevant GCP regulations.

Exclusion criteria

Exclusion criteria: (1) Immunodeficiency disease, or those who have used immunosuppressive agents or glucocorticoids within the past 3 months; (2) Preparing pregnant, pregnant and lactating women; (3) Patients with allergies (referring to allergies to two or more medicines, foods or known ingredients in this study); (4) Patients with mental illness, or have no cognitive ability; (5) Patients with an estimated survival time of less than 48 hours from the start of screening; (6) Those who have been intubated or mechanically ventilated at the time of screening; (7) Obvious symptoms of heart, liver, kidney or various other systems, ALT, AST exceed 1.5 times the upper limit of normal value; (8) Believed to be not suitable to participate in clinical trials by investigator.

Design outcomes

Primary

MeasureTime frame
Time of viral nucleic acid turns negative;Antipyretic time;

Secondary

MeasureTime frame
Arterial Oxygen Saturation;Critical (severe or critical) conversion rate;Inflammation index (CRP);The disappearance rate and time of cough symptoms;Clinical recovery time;

Countries

China

Contacts

Public ContactHongzhou Lu, Xiaorong Chen

Shanghai Public Health Clinical Center

luhongzhou@fudan.edu.cn+86 18930810088

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026